Colour, copper and repair
These compounds ask skin to do different things. A useful comparison starts with those physical differences.
Where each investigation starts
I can put these subjects on the same page because skin connects them. I cannot put them in a league table: the experiments tested different material and different outcomes. Melanotan II stimulates pigment production; GHK-Cu research includes copper delivery and supporting tissue; GLOW brings several repair mechanisms into an untested mixture.
The actual encounter with tissue is more informative than the shared word “peptide”. A compound on the outside faces a barrier. A compound acting throughout the body can affect more than the surface. A mixture brings its own chemistry as well as the biology of its ingredients.
Measured outcomes
| Subject | Test setting | Measured result |
|---|---|---|
| Melanotan II | Three healthy men | Darker skin in two of three men |
| GHK-Cu | Removed human skin | Copper crossing skin and retained in the dermis |
| GHK mixture | 45 men with male-pattern hair loss | Greater hair-count increases than placebo |
| BPC-157 ingredient | Cells, chick membranes and rats | Blood-vessel growth and related signalling |
| GLOW blend | No controlled human trial in this record | Combined benefits and harms remain unmeasured |
The distinction between GHK and GHK-Cu matters in this table. The hair trial used GHK with 5-aminolevulinic acid. The copper penetration experiment measured copper from GHK-Cu in isolated tissue. They cannot exchange their results just because their names overlap.
What remains in the tissue
Retention can have very different meanings. In the isolated-skin copper experiment, a depot was a measured reservoir within the dermis. In a Melanotan II case report, pigment remained in the gums at reduced intensity three months after cessation, while inner-cheek colour had begun fading by 28 days. These findings concern different substances, different tissue and different methods.
An aesthetic result has a life after it appears, and its retreat can be as revealing as its arrival. How it recedes, where material stays and what other effects accompany it can matter as much as the initial change. GLOW has no corresponding follow-up of a tested, fixed blend in these papers.
The safety comparison
Melanotan II has a clinical report of kidney infarction alongside its small human studies. GHK-Cu’s human record is concentrated on topical preparations, with broader claims drawing heavily on laboratory work. For GLOW, the review naming the constituents describes scarce rigorous human safety data and the potential for serious harm in the wider unapproved-peptide field.
I see reasons for different questions here, rather than a winning compound. For GHK-Cu, delivery and formulation shape the experiment. For Melanotan II, the accompanying body effects deserve the same attention as the pigment. For GLOW, the combination itself still awaits a controlled human test.